Jaguar Health, Inc. - JAGX STOCK NEWS

Jaguar Health has announced the issuance of new patents in Europe and Australia to bolster IP protection for its drug crofelemer, aimed at treating Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs). The European patent covers treatment methods for SBS and associated conditions, while the Australian patent focuses on CDDs. The patents enhance Jaguar's intellectual property portfolio, which already includes approximately 200 patents issued or pending. This development supports ongoing proof-of-concept studies of crofelemer in the US, EU, and MENA regions, with results expected in 2024 and 2025. These studies could facilitate early patient access to crofelemer in countries with applicable guidelines. SBS and MVID patients suffer from severe symptoms requiring intensive medical support, highlighting the potential impact of these patents on patient care.

Jaguar Health (NASDAQ: JAGX) has announced that it has regained compliance with Nasdaq's bid price requirement as of June 25, 2024, ensuring its securities remain listed and traded on Nasdaq. The company is also set to report results from its pivotal phase 3 OnTarget trial for the cancer supportive care drug crofelemer by July 23, 2024. Jaguar's CEO, Lisa Conte, emphasized the importance of maintaining their Nasdaq listing and mentioned an upcoming investor webcast that will discuss Jaguar's cancer supportive care portfolio, featuring insights from scientific experts and patient advocates.

Jaguar Health announced the approval of all proposals at its Annual Meeting of Stockholders held on June 21, 2024. Five proposals were submitted and approved, details of which are available in the company's proxy statement filed with the SEC. Jaguar will report results from its pivotal phase 3 OnTarget trial for the cancer supportive care drug crofelemer by July 23, 2024. An investor webcast on or before this date will include updates on Jaguar's cancer supportive care portfolio, featuring insights from the scientific team, patient advocates, and oncology experts. In celebration of World Rainforest Day on June 22, Jaguar shared a RealPharma podcast interview with Dr. Steven King, highlighting his ethnobotanical research and the medicinal use of plants by indigenous Amazonian communities.

Jaguar Health announced it will release the results of its phase 3 OnTarget trial for crofelemer, aimed at preventing diarrhea in cancer patients, by July 23, 2024. The study involves patients with solid tumors undergoing targeted therapy, with or without chemotherapy. An investor webcast will present the trial results and updates on Jaguar's cancer supportive care initiatives. Key points include Jaguar's in-license of Gelclair for oral mucositis, a commercialization deal with GEN for crofelemer in Turkey, and the 'Make Cancer Less Shitty' advocacy program. The company emphasizes the importance of supportive care in improving cancer patients' quality of life.

Jaguar Health announced a new employee inducement grant under Nasdaq Listing Rule 5635(c)(4), effective June 4, 2024. The company has granted 1,111 restricted stock units (RSUs) to a new employee, which will vest over one year. This grant, approved by Jaguar's Compensation Committee, was made to attract the new hire. The vesting of these RSUs is contingent upon the employee's continued service with Jaguar through the vesting period.

Jaguar Health has announced an out-licensing agreement with Magdalena Biosciences for a botanical drug candidate aimed at treating schizophrenia. This drug shows antipsychotic activity with a unique mechanism of action compared to current FDA-approved therapies. Under the deal, Jaguar will receive 10% of all upfront and milestone payments, excluding certain commercial milestones and R&D reimbursements. Additionally, Jaguar will earn royalties on net sales if the drug is FDA-approved and commercialized. The U.S. schizophrenia market is forecasted to reach $8.06 billion by 2030. Jaguar will present at the Lytham Partners Spring 2024 Investor Conference on May 30.

Jaguar Health announced that a third-party, investigator-initiated study of its plant-based drug, crofelemer, showed positive results for treating functional diarrhea. The study revealed that twice-daily oral doses of crofelemer significantly reduced abdominal pain and improved stool consistency compared to a placebo. Functional diarrhea, a chronic condition affecting 4.7% of adults globally, currently lacks effective treatments. Napo Pharmaceuticals, a subsidiary of Jaguar, is planning to submit an abstract of the study to a peer-reviewed journal. Crofelemer is derived from the red bark sap of the Croton lechleri tree, harvested sustainably in the Amazon Rainforest.

Jaguar Health (NASDAQ: JAGX) is expanding its commercial footprint in cancer supportive care. The company will showcase Gelclair, an FDA-approved product for oral mucositis, at the ASCO Annual Meeting from May 31 to June 4. Gelclair, which Jaguar licensed for the U.S. market, is set for commercial launch in Q3 2024. Oral mucositis, a painful side effect of cancer treatment, affects up to 90% of head and neck cancer patients. Jaguar is also nearing top-line results for its phase 3 OnTarget trial of crofelemer to prevent cancer therapy-related diarrhea.

With 18 million Americans living with a cancer diagnosis, and over 2 million new cases expected in 2024, Jaguar's focus on improving cancer patient quality of life is significant. The company emphasizes Gelclair's ability to manage pain without numbing or stinging, potentially reducing hospitalizations and treatment interruptions. The economic impact of oral mucositis is considerable, with costs exceeding $17,000 for head and neck cancer patients.

Jaguar Health will implement a 1-for-60 reverse stock split of its common stock on May 23, 2024, following approval at the April 2024 Special Meeting of Stockholders. The split aims to support compliance with Nasdaq listing standards and attract institutional investors. Post-split, the stock will trade under the symbol JAGX with a new CUSIP number: 47010C805. Fractional shares will be settled in cash.

Equiniti Trust Company will handle the exchange process for stockholders holding certificates. No action is required for those with shares in brokerage accounts.